Already a Bloomberg.com user?
Sign in with the same account.
Don't have an account?
Help! I can't access my account.
June 9 (Bloomberg) -- Merck & Co. agreed to buy Idenix Pharmaceuticals Inc. for about $3.85 billion to add experimental drugs to treat hepatitis C. Adam Johnson reports on Bloomberg Television’s “Bloomberg Surveillance.” (Source: Bloomberg)
On Air Now
©2014 Bloomberg L.P. All Rights Reserved. Made in NYC